Close Menu

NEW YORK – MapKure announced a partnership with Personalis on Monday to use its NGS assay, the NeXT Platform, to screen patients for a Phase I clinical trial of its BRAF inhibitor, BGB-3245.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.